#USA #Nashville #Barrett's Esophagus #Castle Biosciences #TissueCypher

Revolutionizing Barrett's Esophagus Management with TissueCypher

Recent studies showcased at the ACG 2026 Annual Scientific Meeting have significantly advanced our understanding of how to manage Barrett's Esophagus (BE), a precancerous condition that can lead to esophageal adenocarcinoma (EAC). Castle Biosciences, a pioneering healthcare company, introduced data indicating that their TissueCypher® test offers a robust assessment of patient risk beyond traditional pathology findings, allowing for more personalized treatment approaches.

Dr. Virendra Joshi, a gastroenterologist and one of the study authors from Emory University, emphasized that standard endoscopic biopsy results do not always reflect a patient’s true risk of progression. “The studies presented at ACG demonstrate how TissueCypher can complement standard pathology,” Dr. Joshi stated. “It provides objective molecular risk information that is crucial for guiding treatment strategies for patients with Barrett’s esophagus.”

Understanding Barrett’s Esophagus

BE occurs when the tissue lining the esophagus undergoes changes (metaplasia) that can be precursors to EAC. Patients diagnosed with non-dysplastic Barrett's esophagus often face routine monitoring via endoscopies, typically every three to five years, as their risk of progression is considered low based on histopathological assessments alone. However, recent research calls this approach into question.

Key Findings from TissueCypher Studies

Three critical studies presented in Nashville revealed the effectiveness of TissueCypher in identifying patients at higher risk for disease progression:

1. Missed Diagnoses: A case reported by Dr. Salih Samo from the University of Kansas demonstrated that a patient deemed low risk based on standard biopsy actually had a 62% probability of progressing to high-grade dysplasia (HGD) within five years, highlighted by a TissueCypher test. This finding led to earlier intervention decisions, including repeat endoscopies that uncovered previously undetected HGD.

2. Real-World Impact: Another cohort study led by Dr. Shree Patel at Emory University indicated significant differences in risk stratification. TissueCypher classified 83% of patients as low risk—contrasting drastically with only 31% identified by a traditional clinicopathological risk model. The recommendations for management changed for 96% of patients based on TissueCypher findings, illustrating its impact on clinical decision-making.

3. Early Interventions: In a complex case where biopsy results varied, TissueCypher's assessment prompted timely intervention that led to complete eradication of precancerous lesions in a patient with conflicting diagnoses. Such cases exemplify TissueCypher's capability to clear up ambiguities in patient risk assessment, potentially preventing disease progression through earlier treatment initiation.

The Importance of Molecular Risk Assessment

TissueCypher uses an advanced AI-derived approach to analyze protein biomarkers and tissue architecture from routine endoscopic biopsies. This innovative test delivers a personalized five-year risk projection for patients diagnosed with non-dysplastic Barrett's esophagus, indefinite for dysplasia, or low-grade dysplasia. The data tells a compelling story about integrating molecular insights into routine clinical practice for BE management, facilitating patient-specific care.

Dr. Patel affirms that TissueCypher is transforming how gastroenterologists assess risk, stating that it “provides essential risk information that can shape individual patient management and improve patient outcomes.” These assertions resonate across the data, prompting a shift toward more tailored and effective gastrointestinal care.

Conclusion

The ACG 2026 presentations have set the stage for a new era in managing Barrett's Esophagus. With emerging data advocating for innovative tools like TissueCypher, patients will likely benefit from a more nuanced understanding of their disease risk and opportunities for timely interventions. As Castle Biosciences continues to unfold the capabilities of TissueCypher, clinicians and patients may look forward to a future where personalized care in gastroenterology is the standard, ensuring that each patient is treated based on their unique molecular risk profile.

For further insights, Castle Biosciences invites attendees to visit Booth 1706 and engage with ongoing discussions surrounding TissueCypher's potential in clinical practice.